Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer Keeps Teva's Generic Lipitor Out Of U.K. For Now; Wins Six Month Patent Extension

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer's block against Teva's generic Lipitor in the U.K. will remain in place until a full trial later this year; pharmacies caught between the warring factions.

You may also be interested in...

Lipitor Generics Watch: FDA Has Yet To Approve ANDA For The World's #1 Drug

Mylan had pointed to June 28 as the earliest date FDA could approve atorvastatin ANDAs; the agency is continuing discussions with Ranbaxy about its exclusivity status.

Pfizer Blocks Teva's Generic Lipitor In The U.K.

Pfizer wins temporary injunction on Teva's U.K launch of generic atorvastatin; hearing scheduled for July.

Lipitor Will Fade, Not Fall Off The Patent Cliff In Europe

Lipitor's European sales won't all disappear overnight, But the strong post-patent performance in Spain isunlikely to be replicated either.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts